ImaginAB and Eli Lilly announced a pre-clinical collaboration to use ImaginAb’s immune imaging agent IAB22M2C to study new T-cell therapies cancer. Continue reading
ImaginAB and Eli Lilly announced a pre-clinical collaboration to use ImaginAb’s immune imaging agent IAB22M2C to study new T-cell therapies cancer. Continue reading